Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth

  • Authors:
    • Alissa Routhier
    • Michelle Astuccio
    • Deanna Lahey
    • Nicholas Monfredo
    • Alyssa Johnson
    • William Callahan
    • Amy Partington
    • Kelly Fellows
    • Lori Ouellette
    • Sofiela Zhidro
    • Carrie Goodrow
    • Alexis Smith
    • Kaitlyn Sullivan
    • Peter Simone
    • Leo Le
    • Bora Vezuli
    • Micheline Zohni
    • Elizabeth West
    • Daniel Gleason
    • Brad Bryan
  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/or_00000708
  • Pages: 861-867
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Primarily through in vitro studies, the Rho-family of small GTPases and their effector proteins have been implicated in mediating oncogenic properties of cancer cells. We sought to determine if pharmacological inhibition of the RhoA effector proteins known as Rho-kinases (ROCK) with the small molecule inhibitor Y-27632 could inhibit melanoma in vitro and in vivo. We demonstrate that Y-27632 treatment of a panel of melanoma cells alters cellular morphology leading to spindly cells with decreased lamellipodia and increased filopodia formation. Y-27632 treatment decreases invasion and alters cell survival of cultured melanoma cells. IP injection of Y-27632 in tumor-bearing mice resulted in a reduction in melanoma tumor volume compared to control treated mice. These findings suggest that ROCK inhibition can reduce melanoma tumorigenicity.

Related Articles

Journal Cover

March 2010
Volume 23 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, Callahan W, Partington A, Fellows K, Ouellette L, Zhidro S, Zhidro S, et al: Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep 23: 861-867, 2010
APA
Routhier, A., Astuccio, M., Lahey, D., Monfredo, N., Johnson, A., Callahan, W. ... Bryan, B. (2010). Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncology Reports, 23, 861-867. https://doi.org/10.3892/or_00000708
MLA
Routhier, A., Astuccio, M., Lahey, D., Monfredo, N., Johnson, A., Callahan, W., Partington, A., Fellows, K., Ouellette, L., Zhidro, S., Goodrow, C., Smith, A., Sullivan, K., Simone, P., Le, L., Vezuli, B., Zohni, M., West, E., Gleason, D., Bryan, B."Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth". Oncology Reports 23.3 (2010): 861-867.
Chicago
Routhier, A., Astuccio, M., Lahey, D., Monfredo, N., Johnson, A., Callahan, W., Partington, A., Fellows, K., Ouellette, L., Zhidro, S., Goodrow, C., Smith, A., Sullivan, K., Simone, P., Le, L., Vezuli, B., Zohni, M., West, E., Gleason, D., Bryan, B."Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth". Oncology Reports 23, no. 3 (2010): 861-867. https://doi.org/10.3892/or_00000708